tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Korro Bio initiated with a Buy at Chardan

Chardan analyst Keay Nakae initiated coverage of Korro Bio (KRRO) with a Buy rating and $25 price target Korro is an “intriguing small-cap story” that now trades at a compelling entry point, the analyst tells investors in a research note. The firm cites the potential of the company’s enabling design platform for ADAR RNA base-editing therapeutics for the Buy rating.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1